The study on semaglutide, a GLP-1 receptor agonist, shows significant benefits in preventing kidney disease, cardiovascular events, and mortality in patients with CKD and type 2 diabetes. High-risk patients showed a 24% lower risk of major kidney events with semaglutide. The trial stopped early due to clear efficacy, and further analyses favored semaglutide. Adverse events were lower in the semaglutide group. The findings offer hope for improving treatment strategies for diabetic complications. Despite some caveats, the results provide reassurance about using semaglutide in combination with current treatments. Diabetes-related kidney disease is a significant global issue that requires urgent attention.
Source link
Semaglutide Significantly Improves Chronic Kidney Disease
